A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer

Grants

Funding Acknowledgements

The COIN and COIN-B trials were funded by Cancer Research UK and the Medical Research Council and were conducted with the support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B translational studies were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and Health Research Cancer Genetics Biomedical Research Unit (2011-2014) (all awarded to J.P.C.). We thank the patients and their families who participated in COIN and COIN-B, and gave their consent for this research, and the investigators and pathologists throughout the UK who submitted samples for assessment. N.A.A., B.F.M. and S.M.W. were funded and supported by KFSHRC. At the Institute of Cancer Research, the work was supported by Cancer Research UK (C1298/A8362 - Bobby Moore Fund for Cancer Research UK). Additional support was provided by the National Cancer Research Network and the NHS via the Biological Research Centre of the National Institute for Health Research at the Royal Marsden Hospital NHS Trust. N.W. and B.K. were in receipt of PhD studentships from the ICR. B.K additionally receives funding from the Sir John Fisher Foundation. In Edinburgh the work was supported by Programme Grant funding from Cancer Research UK (C348/A12076). In Oxford additional funding was provided by the Oxford Comprehensive Biomedical Research Centre (C.P. and I.P.M.T.) and the EU FP7 CHIBCHA grant (I.P.M.T.). Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford was provided by grant (090532/Z/09/Z). We are grateful to many colleagues within UK Clinical Genetics Departments (for CORGI) and to many collaborators who participated in the VICTOR and QUASAR2 trials. We also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from the European Union (FP7/207-2013) under grant 258236 and FP7 collaborative project SYSCOL and COST Action BM1206 in the UK is also acknowledged. The work of the Colon Cancer Family Registry CFR was supported by grant UM1 CA167551 from the National Cancer Institute, National Institutes of Health and through cooperative agreements with members of the Colon CFR and Principal Investigators. Collaborating centers include the Australasian Colorectal Cancer Family Registry (U01/U24 CA097735), the USC Colorectal Cancer Family Registry (U01/U24 CA074799), Mayo Clinic Cooperative Familial Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (U01/U24 CA074783), the Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), and the University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806). The Colon CFR GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (U01 CA122839 and R01 CA143237 to GC). This study made use of genotyping data from the 1958 Birth Cohort, kindly made available by the Wellcome Trust Case Control Consortium 2. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk/. The results published here are in whole or part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions which constitute the TCGA research network can be found at http://cancergenome.nih.gov/. Finally, we would like to thank all individuals who participated in the study.